Immix Biopharma, Inc.
IMMX
$4.15
$0.184.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.08M | 2.75M | 2.71M | 3.61M | 2.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.66M | 6.72M | 4.68M | 4.99M | 7.39M |
| Operating Income | -7.66M | -6.72M | -4.68M | -4.99M | -7.39M |
| Income Before Tax | -7.58M | -6.61M | -4.53M | -4.80M | -7.14M |
| Income Tax Expenses | 7.70K | 8.90K | 9.80K | 10.80K | 11.10K |
| Earnings from Continuing Operations | -7.59M | -6.62M | -4.54M | -4.81M | -7.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 0.00 | -- |
| Net Income | -7.59M | -6.62M | -4.54M | -4.81M | -7.15M |
| EBIT | -7.66M | -6.72M | -4.68M | -4.99M | -7.39M |
| EBITDA | -7.57M | -6.66M | -4.64M | -4.97M | -7.39M |
| EPS Basic | -0.24 | -0.22 | -0.15 | -0.16 | -0.24 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.10 | -0.10 | -0.15 |
| EPS Diluted | -0.24 | -0.22 | -0.15 | -0.16 | -0.24 |
| Normalized Diluted EPS | -0.15 | -0.14 | -0.10 | -0.10 | -0.15 |
| Average Basic Shares Outstanding | 31.93M | 29.98M | 29.70M | 29.56M | 29.42M |
| Average Diluted Shares Outstanding | 31.93M | 29.98M | 29.70M | 29.56M | 29.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |